All The Claims

1. A module for a green roof system comprising:
a tray thermoformed from a blanket of non-woven polyethylene terephthalate plastic fibers, the tray comprising:
a bottom surface;
a sidewall extending upward from the bottom surface to a lip; and
one or more raised portions separating the bottom surface into a plurality of cells;
wherein the one or more raised portions form water drainage channels;

growing media comprising at least one of expanded shale, expanded clay, expanded slate, sand, wood fines, coir, compost, and biosolids;
a seed retaining mesh formed of the polyethylene terephthalate plastic fibers;
a plurality of seeds; and
a top cover formed of the polyethylene terephthalate plastic fibers, the top cover being attached to the lip of the tray;
wherein the polyethylene terephthalate plastic fibers used to make the tray, seed retaining mesh, and top cover are sourced entirely from recycled material;
wherein the tray is porous, allowing water to pass through at least a portion of the bottom surface while prohibiting passage of particles having an average diameter between about 0.02 mm to about 9.5 mm through the bottom surface.
2. The module according to claim 1, wherein the drainage channels are formed below the bottom surface of the tray.
3. The module according to claim 1, wherein at least one of the seeds and growing media is selected based on the climate of a geographic region where the module is installed.
4. The module according to claim 1, wherein the polyethylene terephthalate plastic fibers comprise fibers of at least three different sizes.
5. The module according to claim 4, wherein the first fiber size is about 2.5 to 4 denier, the second fiber size is about 5 to 8 denier, and the third fiber size is about 9 to 13 denier.
6. The module according to claim 4, wherein the first fiber size is about 2.5 denier, the second fiber size is about 6 denier, and the third fiber size is about 9 denier.
7. The module according to claim 5, wherein one third of the volume of the polyethylene terephthalate plastic fibers are a first fiber size, one third are a second fiber size, and one third are a third fiber size.
8. The module according to claim 1, wherein the gaps between the polyethylene terephthalate plastic fibers of the tray are about 0.01 mm to about 0.04 mm.
9. A tray for a module of a green roof system comprising:
a bottom surface;
a sidewall extending upward from the perimeter of the bottom surface to a lip; and
one or more raised portions of the bottom surface that divide the bottom surface into a plurality of cells;
wherein at least the bottom surface is porous and has a porosity of about 50 percent to about 80 percent; and
wherein the bottom surface prohibits the passage of particles larger than about 0.01 mm in diameter.
10. The tray according to claim 9, wherein at least the bottom surface of the tray is formed from a non-woven blanket of plastic fibers.
11. The tray according to claim 10, wherein the plastic fibers are polyethylene terephthalate plastic fibers.
12. The tray according to claim 11, wherein the polyethylene terephthalate plastic is post-consumer plastic.
13. The tray according to claim 10, wherein the plastic fibers comprise at least three different sizes of plastic fibers.
14. The tray according to claim 13, wherein the first fiber size is about 2.5 to 4 denier, the second fiber size is about 5 to 8 denier, and the third fiber size is about 9 to 13 denier.
15. The tray according to claim 13, wherein the first fiber size is about 2.5 denier, the second fiber size is about 6 denier, and the third fiber size is about 9 denier.
16. The tray according to claim 14, wherein one third of the volume of the plastic fibers are a first fiber size, one third are a second fiber size, and one third are a third fiber size.
17. The tray according to claim 9, wherein the bottom surface prohibits passage of particles having an average diameter between about 0.02 mm to about 9.5 mm through the bottom surface.
18. A method of making a tray for a module of a green roof system, the method comprising:
providing a plurality of plastic fibers;
forming a non-woven blanket from the plastic fibers;
cutting the non-woven blanket to a desired size; and
forming the non-woven blanket into a tray having:
a bottom surface;
a sidewall extending upward from the perimeter of the bottom surface to a lip; and
one or more raised portions of the bottom surface that divide the bottom surface into a plurality of cells.
19. The method of claim 18, wherein forming the non-woven blanket into a tray involves heating the non-woven blanket to cause at least a portion of the plastic fibers to form connections through melting.
20. The method of claim 18, wherein the plastic fibers are polyethylene terephthalate plastic fibers.
21. The method of claim 18, wherein the plastic fibers comprise at least three different size plastic fibers.
22. The method of claim 18, wherein a first fiber size is about 2.5 to 4 denier, a second fiber size is about 5 to 8 denier, and a third fiber size is about 9 to 13 denier.
23. The method of claim 18, wherein a first fiber size is about 2.5 denier, a second fiber size is about 6 denier, and a third fiber size is about 9 denier.
24. A green roof system comprising:
a plurality of modules of claim 1;
wherein the plurality of modules are arranged on a roof top; and
wherein water drainage channels are formed between the tray and rooftop.
25. A module for a green roof system comprising:
a tray thermoformed from a blanket of non-woven polyethylene terephthalate plastic fibers, the tray comprising:
a bottom surface;
a sidewall extending upward from the bottom surface to a lip; and
one or more raised portions separating the bottom surface into a plurality of cells;
wherein the one or more raised portions form water drainage channels;

growing media comprising at least one of expanded shale, expanded clay, expanded slate, sand, wood fines, coir, compost, and biosolids;
a seed retaining mesh; and
a plurality of seeds;
wherein the tray is porous, allowing water to pass through at least a portion of the bottom surface while prohibiting passage of particles having an average diameter between about 0.02 mm to about 9.5 mm through the bottom surface.
26. The module according to claim 25, wherein the gaps between the polyethylene terephthalate plastic fibers of the tray are about 0.01 mm to about 0.04 mm.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of preparation of a feed stock for a process comprising separating a formaldehyde-containing product from a formaldehyde solution comprising formaldehyde, water and methanol, wherein said formaldehyde-containing product contains substantially less water than said formaldehyde solution, comprising distilling said formaldehyde solution in the presence of a water entraining compound, wherein said water entraining compound and said formaldehyde-containing product form the basis of the feed stock for the said process.
2. A process as claimed in claim 1, wherein said formaldehyde solution contains methanol at a molar ratio of methanol to formaldehyde of 0.3-1.5:1.
3. A process as claimed in claim 1, wherein the formaldehyde solution is pre-mixed with a quantity of methanol before the distillation process such that the molar ratio of methanol to formaldehyde is in the range 0.3-1.5:1.
4. A process as claimed in claim 1, wherein the water entraining compound is selected from a group consisting of a saturated or unsaturated carboxylic acid, an ester and a carbonyl compound.
5. A process as claimed in claim 4, wherein the water entraining compound is methyl propionate or methyl methacrylate.
6. A process as claimed in claim 1, wherein the ratio of water entraining compound to formaldehyde in the base of the column is in the range 5:1-20:1 by mass.
7. A process as claimed in claim 1, wherein a liquid sidestream containing the greater part of the water contained in said formaldehyde solution is withdrawn from the distillation process.
8. A process as claimed in claim 1, wherein said process is integrated with a further process so that the formaldehyde-containing product is supplied directly to said further process.
9. A process as claimed in claim 8, wherein said further process is a process for the production of methyl methacrylate.
10. A process for the production of methyl methacrylate by the reaction of formaldehyde with methyl propionate in the presence of methanol and of a suitable catalyst, wherein said formaldehyde comprises a formaldehyde-containing product produced from a formaldehyde solution by means of distilling said formaldehyde solution in the presence of methyl propionate, wherein said formaldehyde solution contains methanol at a molar ratio of methanol to formaldehyde of 0.3-1.5:1 and wherein the formaldehyde-containing product contains substantially less water than said formaldehyde solution.
11. A formaldehyde containing product produced from an aqueous formaldehyde solution feedstock which contains a greater concentration of water than said formaldehyde containing product, said product being obtained by distilling said aqueous formaldehyde solution with a water entraining compound.
12. A formaldehyde containig product as claimed in claim 11, wherein the watrer entraining compound is selected from the group consisting of a saturated or unsaturated carboxylic acid, an ester and a carbonyl compound.
13. A formaldehyde containing product as claimed in claim 12, wherein the water entraining compound is methyl propionate or methyl methacrylate.

1. A sunscreen composite particle comprising:
a) an UVA sunscreen suitable to undergo keto-enol tautomerization;
b) a condensation polymerizable resin; and
c) a solvent, the solvent being one in which the UVA sunscreen is soluble in and one having a dielectric constant from about 5.5 to about 9
wherein the particle imparts UVA and UVB sunscreen protection and is substantially free of supplied UVB sunscreen.
2. The sunscreen composite particle according to claim 1 wherein the UVA sunscreen can dissolve in the solvent to yield a solution which is at least about 15% by UVA sunscreen based on total weight of sunscreen and solvent.
3. The sunscreen composite particle according to claim 1 wherein the sunscreen is dibenzoyl methane or a derivative thereof.
4. The sunscreen composite particle according to claim 1 wherein the sunscreen has the formula:
where
R is H or a C1-3 alkyl;
R1 is a linear or branched C1-6 alkyl; and
each R2 is independently a C1-4 alkyl and i is zero or 1.
5. The sunscreen composite particle according to claim 1 wherein the sunscreen is 4-(1,1-dimethylethyl)-4\u2032-methoxydibenzoylmethane.
6. The sunscreen composite particle according to claim 1 wherein the resin is a polyester or polyamide, and the solvent is an imide or phthalimide.
7. The sunscreen composite particle according to claim 1 wherein the solvent has the formula:
where R7 is a C1-8 linear or branched alkyl and each R8 is independently H, OH, C1-3 alkoxy or a C1-5 alkyl group.
8. The sunscreen composite particle according to claim 1 wherein the solvent has the formula:
where R9 is a C1-6 linear or branched alkyl and each R10 is independently H or a C1-3 alkyl.
9. The sunscreen composite particle according to claim 8 wherein the solvent is butylisopropyl phthalimide.
10. A composition for providing UVA and UVB protection, the composition comprising a sunscreen composite particle comprising:
a) an UVA sunscreen suitable to undergo keto-enol tautomerization;
b) a condensation polymerizable resin; and
c) a solvent, the solvent being one in which the UVA sunscreen is soluble in and one having a dielectric constant from about 5.5 to about 9
wherein the particle imparts UVA and UVB sunscreen protection and is substantially free of supplied UVB sunscreen.
11. The composition according to claim 10 wherein the UVA sunscreen can dissolve in the solvent to yield a solution which is at least about 15% by UVA sunscreen based on total weight of sunscreen and solvent.
12. The composition according to claim 10 wherein the sunscreen is dibenzoyl methane or a derivative thereof.
13. The composition according to claim 10 wherein the sunscreen has the formula:
where
R is H or a C1-3 alkyl;
R1 is a linear or branched C1-6 alkyl; and
each R2 is independently a C1-4 alkyl and i is zero or 1.
where
R is H or a C1-3 alkyl;
R1 is a linear or branched C1-6 alkyl; and
R2 is a C1-4 alkyl.
14. The composition according to claim 10 wherein the sunscreen is 4-(1,1-dimethylethyl)-4\u2032-methoxydibenzoylmethane.
15. The composition according to claim 10 wherein the resin is a polyester or polyamide, and the solvent is an imide or phthalimide.
16. The composition according to claim 10 wherein the solvent has the formula:
where R7 is a C1-8 linear or branched alkyl and each R8 is independently H, OH, C1-3 alkoxy or a C1-5 alkyl group.
17. The composition according to claim 10 wherein the solvent has the formula:
where R9 is a C1-6 linear or branched alkyl and each R10 is independently H or a C1-3 alkyl.
18. The composition according to claim 17 wherein the solvent is butylisopropyl phthalimide.
19. The composition according to claim 16 wherein the solvent is a di- or tri-imide derived from the solvent represented by formula.
20. A method for obtaining UVA and UVB protection comprising the step of topically applying to skin the composition of claim 10.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1-118. (canceled)
119. A therapeutic administration system comprising:
a processor;
one or more instructions operable by the processor to obtain a flow-change-indicative measurement; and
one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement.
120. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to program an implantable device.
121. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to obtain turbulence-indicative auditory value as the flow-change-indicative measurement.
122. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to detect one or more conditions optically.
123. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to detect one or more force-change-indicative values.
124. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to decide upon at least one of the one or more clot-reducing agents in response to obtaining an anomalous value as the flow-change-indicative measurement.
125. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.
126. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
127. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions responsive to a flow-force-responsive element.
128. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions responsive to an optical sensor.
129. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions responsive to an auditory sensor.
130. The therapeutic administration system of claim 119, further comprising:
a wireless-communication device.
131. The therapeutic administration system of claim 119, further comprising:
a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
132. The therapeutic administration system of claim 119, further comprising:
an implantable valve comprising at least one dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
133. The therapeutic administration system of claim 119, further comprising:
an implant-site-targeting dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
134-144. (canceled)
145. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to signal at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation; and
one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
146. The therapeutic administration system of claim 145, further comprising:
an implantable valve comprising at least a first dispenser operable for dispensing at least a lytic material;
a second dispenser operable for targeting an implant site; and
a wireless-communication device operable for communicating a selection of the first dispenser or the second dispenser.
147. The therapeutic administration system of claim 119, further comprising:
an implantable valve comprising at least a first dispenser operable for dispensing at least a lytic material;
a second dispenser operable for targeting an implant site by dispensing at least the lytic material; and
a wireless-communication device operable for communicating a selection of the first dispenser or the second dispenser.
148-162. (canceled)
163-173. (canceled)
174-176. (canceled)
177. A therapeutic administration method comprising:
obtaining a flow-change-indicative measurement; and
signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement.
178. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:
programming an implantable device.
179. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:
obtaining a turbulence-indicative auditory value as the flow-change-indicative measurement.
180. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:
detecting one or more conditions optically.
181. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:
detecting one or more force-change-indicative values.
182. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:
deciding upon at least one of the one or more clot-reducing agents in response to obtaining an anomalous value as the flow-change-indicative measurement.
183. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:
signaling at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.
184. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:
causing one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
185-189. (canceled)
190. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:
deciding upon at least one of the one or more clot-reducing agents in response to obtaining an anomalous value as the flow-change-indicative measurement;
signaling at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation; and
causing one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
191-322. (canceled)
323. The therapeutic administration system of claim 119, further comprising:
a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
324. The therapeutic administration system of claim 119, further comprising:
an implant-site-targeting dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
325. The therapeutic administration system of claim 122 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to obtain a turbulence-indicative auditory value as the flow-change-indicative measurement.
326. The therapeutic administration system of claim 123 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
327. The therapeutic administration system of claim 123, further comprising:
a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
328. The therapeutic administration system of claim 125 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
329. The therapeutic administration system of claim 128, further comprising:
a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
330. The therapeutic administration system of claim 128, further comprising:
a wireless-communication device.
331. The therapeutic administration system of claim 130 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to obtain a turbulence-indicative auditory value as the flow-change-indicative measurement.
332. The therapeutic administration system of claim 131 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to obtain a turbulence-indicative auditory value as the flow-change-indicative measurement.
333. The therapeutic administration system of claim 131 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to signal at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.
334. The therapeutic administration system of claim 132 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to signal at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.
335. The therapeutic administration system of claim 133 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
336. The therapeutic administration system of claim 133, further comprising:
a wireless-communication device.
337. The therapeutic administration system of claim 133, further comprising:
a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.